Vivek Ramaswamy speaks at an Endpoints News event in Shanghai, October 2018 (Endpoints News, Pharmcube)
Backed by a $200M investment from a Korean conglomerate, Vivek Ramaswamy has quietly built a ‘mother ship’ for vant creation — with a whole new strategy in mind
Vivek Ramaswamy built Roivant as the mother ship to a fleet of vants that were largely launched through in-licensing deals — often with the Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
